Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.
DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.
DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.
Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.
The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.
Dexcom, Inc. (NASDAQ: DXCM) announced an expansion of coverage for its Dexcom G6 real-time continuous glucose monitoring (rtCGM) system under the Non-Insured Health Benefits (NIHB) program. This change allows all clients living with type 1 diabetes, beyond the existing restriction for ages 2 to 19, to receive coverage. The initiative aims to improve health outcomes for Indigenous communities, who are disproportionately affected by diabetes, by providing greater access to essential healthcare technology. The Dexcom G6 system aids in better glucose control and reduces the risk of diabetes-related complications.
DexCom, Inc. (NASDAQ: DXCM) has appointed Teri Lawver as the chief commercial officer, a newly created role responsible for global sales, marketing, and customer experience. Ms. Lawver brings over 20 years of leadership experience from Johnson & Johnson, where she successfully grew the immunology business from $11 billion to $16 billion. CEO Kevin Sayer praised her ability to drive growth in the healthcare sector. Ms. Lawver aims to leverage Dexcom's market opportunities and technology to expand the reach of continuous glucose monitoring solutions.
DexCom, Inc. (NASDAQ: DXCM) expects preliminary revenue of at least
DexCom, Inc. (NASDAQ:DXCM) announced that CEO Kevin Sayer will present at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, starting at 2:15 PM EST. The presentation will be webcast live and made available for later viewing on the Dexcom Investor Relations website.
DexCom focuses on diabetes management through its innovative continuous glucose monitoring (CGM) systems, serving users globally from its headquarters in San Diego, California.
Dexcom, Inc. (NASDAQ: DXCM) has launched a new Digital Diabetes Care Program in partnership with Green Shield and The Health Depot. This initiative will provide Green Shield plan members access to the Dexcom G6 real-time continuous glucose monitoring (rtCGM) system along with virtual diabetes management support. Benefits include automated product shipments, preferred pricing, direct billing, and co-payment assistance for Dexcom supplies. The program aims to enhance diabetes management and improve health outcomes by providing personalized support and clinical consultations.
Dexcom G7 has received FDA clearance for all diabetes types in individuals aged two and older. This next-generation continuous glucose monitoring (CGM) system boasts an overall MARD of 8.2%, making it the most accurate FDA-cleared CGM. With a 60% smaller, all-in-one wearable design, it offers a 30-minute sensor warmup and a suite of features including real-time connectivity with wearables and an upgraded mobile app. Furthermore, Dexcom's G7 is the number one covered CGM, with many users incurring low out-of-pocket costs.
Dexcom, Inc. (NASDAQ: DXCM) announces its participation in the Truckers’ Health Adaptive Technology (T.H.A.T.) project to enhance health outcomes for professional truck drivers during National Diabetes Awareness Month. This initiative utilizes real-time continuous glucose monitoring via Dexcom G6 systems, integrating health data to provide personalized virtual care. The T.H.A.T. project will track health metrics of 200 truck drivers and aims to address their higher diabetes risk. This innovative model may be expanded to other high-risk workforces in Canada.
DexCom, Inc. (NASDAQ:DXCM) announced that Matt Dolan, Executive Vice President of Strategy, Corporate Development, and DexCom Labs, will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:30 am (EST). The presentation will provide updates about the company and its innovative continuous glucose monitoring systems aimed at improving diabetes management.
Links to the live webcast and archived presentation will be available on the DexCom Investor Relations website.
On World Diabetes Day, Dexcom (NASDAQ: DXCM) launched a campaign to support the diabetes community through custom continuous glucose monitor (CGM) patches. Celebrities including Henry Slade, Roxy Horner, Sheku Kanneh-Mason, and Eoin Costelloe designed patches to share their personal diabetes stories. The initiative aims to promote visibility and understanding of diabetes, encouraging others to join the movement. Participants can create their designs at UK.SeeDiabetes.com, with the first 500 submissions receiving free patches. Dexcom focuses on real-time diabetes management through innovative CGM technologies.
In November, Dexcom (NASDAQ: DXCM) launches the #SeeDiabetes campaign to enhance access to diabetes care during National Diabetes Awareness Month. This initiative features celebrity advocates like Patti LaBelle and Mark Andrews, who collaborate with artists to create custom Dexcom G6 patches. The campaign aims to raise awareness of coverage challenges for diabetes technology and celebrate the resilience of those living with diabetes. The initiative aligns with World Diabetes Day, advocating for expanded access to continuous glucose monitoring technology, especially following a recent CMS proposal.
FAQ
What is the current stock price of DexCom (DXCM)?
What is the market cap of DexCom (DXCM)?
What does DexCom, Inc. specialize in?
When was DexCom, Inc. founded?
What are some of DexCom's key products?
How do DexCom's CGM systems benefit diabetic patients?
What recent achievements has DexCom made?
How is DexCom integrating its CGM systems with other technologies?
What is the significance of DexCom's strategic partnerships?
What is DexCom's approach to innovation?
How does DexCom support the community?
What financial trends are seen in DexCom's performance?
